Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1995 May;85(1):146–152.

Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack.

K J Marchbank 1, B P Morgan 1, C W van den Berg 1
PMCID: PMC1384038  PMID: 7543447

Abstract

CD59 is the major membrane attack complex of complement (MAC) inhibiting protein on human cells. Its regulation is therefore an important factor in determining the fate of cells at sites of complement activation. We have chosen the K562 erythroleukaemia cell line as a model for studies of the regulation of CD59 expression, because it has previously been reported that phorbol 12-myristate 13-acetate (PMA) caused a 15-fold up-regulation of CD59 mRNA in these cells, implying a substantial capacity for CD59 synthesis. However, no assessment of CD59 protein expression was made in these studies. We show here that surface expression of CD59, as assessed by flow cytometry, was increased four-fold over a 16-hr incubation with PMA, whereas surface expression of decay-accelerating factor (DAF) (CD55) and membrane cofactor protein (MCP) (CD46) was not altered. The newly expressed CD59 was functionally active and anchored through glycosyl-phosphatidylinositol (GPI). Increased expression was dependent upon de novo protein synthesis. CD59 released into cell supernatant was also increased seven-fold by PMA, this 'secreted' CD59 retained its GPI anchor. Non-lethal complement attack did not alter CD59 expression but antibody cross-linking of CD59 caused a rapid loss of the CD59-antibody complexes. However, CD59 was quickly restored to pre-attack levels. This rapid restoration was not dependent upon protein synthesis, suggesting release from preformed stores.

Full text

PDF
146

Images in this article

150Figure 4
on p.150

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cinek T., Horejsí V. The nature of large noncovalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases. J Immunol. 1992 Oct 1;149(7):2262–2270. [PubMed] [Google Scholar]
  2. Davies A., Lachmann P. J. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res. 1993;12(3):258–275. doi: 10.1007/BF02918257. [DOI] [PubMed] [Google Scholar]
  3. Davies A., Morgan B. P. Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector. Biochem J. 1993 Nov 1;295(Pt 3):889–896. doi: 10.1042/bj2950889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989 Sep 1;170(3):637–654. doi: 10.1084/jem.170.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Holguin M. H., Martin C. B., Weis J. H., Parker C. J. Enhanced expression of the complement regulatory protein, membrane inhibitor of reactive lysis (CD59), is regulated at the level of transcription. Blood. 1993 Aug 1;82(3):968–977. [PubMed] [Google Scholar]
  6. Holguin M. H., Wilcox L. A., Bernshaw N. J., Rosse W. F., Parker C. J. Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood. 1990 Jan 1;75(1):284–289. [PubMed] [Google Scholar]
  7. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  8. Meri S., Morgan B. P., Davies A., Daniels R. H., Olavesen M. G., Waldmann H., Lachmann P. J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990 Sep;71(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  9. Morgan B. P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J. 1989 Nov 15;264(1):1–14. doi: 10.1042/bj2640001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Morgan B. P. Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol. 1992;178:115–140. doi: 10.1007/978-3-642-77014-2_8. [DOI] [PubMed] [Google Scholar]
  11. Morgan B. P., Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol. 1994;15(4):369–396. doi: 10.1007/BF01837366. [DOI] [PubMed] [Google Scholar]
  12. Morgan B. P., van den Berg C. W., Davies E. V., Hallett M. B., Horejsi V. Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur J Immunol. 1993 Nov;23(11):2841–2850. doi: 10.1002/eji.1830231118. [DOI] [PubMed] [Google Scholar]
  13. Reiter Y., Fishelson Z. Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP). Mol Immunol. 1992 Jun;29(6):771–781. doi: 10.1016/0161-5890(92)90187-3. [DOI] [PubMed] [Google Scholar]
  14. Sedlák J., Hunáková L., Duraj J., Grófová M., Chorváth B. Modulation of protectin (CD59 antigen) cell surface expression on human neoplastic cell lines. Neoplasma. 1993;40(6):337–340. [PubMed] [Google Scholar]
  15. Toutant J. P., Krall J. A., Richards M. K., Rosenberry T. L. Rapid analysis of glycolipid anchors in amphiphilic dimers of acetylcholinesterases. Cell Mol Neurobiol. 1991 Feb;11(1):219–230. doi: 10.1007/BF00712811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Walter E. I., Roberts W. L., Rosenberry T. L., Ratnoff W. D., Medof M. E. Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage. J Immunol. 1990 Feb 1;144(3):1030–1036. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES